La Roche Posay renewed its partnership with Keke Palmer as the face of its Mela B franchise unveiling the collections expansion while furthering the brand’s commitment to skin tone equity and accessible hyperpigmentation care.
Following a successful collaboration in 2024 that resonated strongly with consumers seeking effective and inclusive skincare solutions, Palmer will continue serving as a leading voice for the franchise through educational and collaborative campaigns, digital storytelling, and community-focused initiatives centered on skin confidence and science-backed skincare.
“Working with La Roche-Posay has been awesome,” says Keke Palmer. “I mean, I get to have fun and lean into the humor of the fact that they are so scientific. So from the beginning, I was kind of peeking in on the conversations with dermatologists, but then also really giving education at the same time in a way that feels nostalgic. I’m excited for people to see as we launch this new moisturizer, that’s so rich and just amazing and nourishing.”
The partnership renewal kicks off in May 2026 with a campaign roll out across La Roche-Posay’s owned social media channels showcasing Keke Palmer as the face of the new Mela B3 launches, along with an exclusive cover launch in partnership with PAPER Magazine to celebrate Palmer’s continued ambassadorship with the brand.
La Roche-Posay is also pleased to announce the Mela B3 range expansion with the launch of the new Mela B3 Double Dose Discoloration Treatment this month. It is an intensive treatment for the face, neck, decolette, and hands that reduces the appearance of age spots, sun spots and dark spots, while also targeting signs of aging. Double the dose with 1% Melasyl™ and Proxylane, the Mela B3 Double Dose is a dark spot revolution for dual efficacy on discoloration and signs of aging.
La Roche-Posay’s award winning Mela B3 franchise is powered by Melasyl, L’Oreal’s multi-patented pigment-correcting ingredient. The Mela B3 products are proven to visibly reduce a range of skin discoloration, including post-acne marks, sunspots, age spots, and even the most persistent dark spots, while respecting the natural tone of all skin types.
In 2024 when Mela B3 first launched, La Roche-Posay surveyed 23,000 people, and nearly half of those people dealing with pigmentary disorders reported a moderate to extremely large effect on their quality of life, according to the study.
Among those with pigmentary disorders such as solar lentigo, melasma, or post-inflammatory hyperpigmentation:
- 22% feel viewed as dirty
- 21% feel people avoid sitting next to them on public transportation
- 23% feel treated differently during administrative procedures
- 21% feel discriminated against at work
The renewed partnership with Keke Palmer will include upcoming campaign launches to continue advocating for skin tone equity and accessible hyperpigmentation care, social-first content, educational conversations with dermatology experts, and appearances tied to the continued rollout of the Melasyl franchise throughout 2026.
For additional information about La Roche-Posay, visit www.laroche-posay.us
